✦ LIBER ✦

Predictors of Therapeutic Remission to Thiopurines in Pediatric Inflammatory Bowel Disease

✍ Scribed by Jennifer M. Choi; Dermot P. McGovern; Edward S. Lee; Dror Berel; Soonil Kwon; Carol J. Landers; Talin Haritunians; Stephan R. Targan; Jerome I. Rotter; Kent D. Taylor; Marla Dubinsky

Book ID: 119432470
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 229 KB
Volume: 140
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(11)60623-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Thiopurines in inflammatory bowel diseas

Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations

✍ A.F.Y. Al Hadithy; N.K.H. de Boer; L.J.J. Derijks; J.C. Escher; C.J.J. Mulder; J 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 270 KB

Initial clinical experience with allopur

Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease

✍ Riad M. Rahhal; Warren P. Bishop 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 1 views

Background: Thiopurines are a mainstay of immunomodulator therapy in inflammatory bowel disease (IBD). Despite their efficacy, some patients may have a poor response due to inability to achieve adequate levels of the active metabolite, 6-thioguanine (6-TGN). Others experience hepatotoxicity, which c

Genome wide association (GWA) predictors

Genome wide association (GWA) predictors of anti-TNFα therapeutic responsiveness in pediatric inflammatory bowel disease

✍ Marla C. Dubinsky; Ling Mei; Madison Friedman; Tanvi Dhere; Talin Haritunians; H 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB

## Background: Interindividual variation in response to anti-tnfalpha therapy may be explained by genetic variability in disease pathogenesis or mechanism of action. recent genome-wide association studies (gwas) in inflammatory bowel disease (ibd) have increased our understanding of the genetic sus

Thiopurine treatment in inflammatory bow

Thiopurine treatment in inflammatory bowel disease: Response predictors, safety, and withdrawal in follow-up

✍ Giuseppe Costantino; Federica Furfaro; Alessandra Belvedere; Angela Alibrandi; W 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 533 KB

Toward a Safer Use of Thiopurines in Inf

Toward a Safer Use of Thiopurines in Inflammatory Bowel Disease

✍ Elena Ricart; Julián Panés 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 157 KB

Clinical usefulness of therapeutic drug

Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease

✍ Melissa L. Haines; Yousef Ajlouni; Peter M. Irving; Miles P. Sparrow; Rosemary R 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 2 views

Background: Circulating concentrations of 6-thioguanine nucleotide (6-TGN) and 6-methyl mercaptopurine (6-MMP) are associated with thiopurine efficacy and may predict toxicity. This study aimed to examine retrospectively the utility of measuring metabolite concentrations in patients with inflammator